- within Criminal Law, Cannabis & Hemp and Immigration topic(s)
On March 23, 2026, Bio-Thera Solutions announced an expansion of its existing partnership with Intas Pharmaceuticals for BAT2506, its golimumab biosimilar referencing Janssen’s SIMPONI®. The updated agreement grants Intas exclusive commercialization and licensing rights in India and marks Bio-Thera’s first biosimilar commercialization partnership focused on India.
Golimumab is a human IgG1 monoclonal antibody that targets tumor necrosis factor alpha (TNF-α), a cytokine involved in inflammatory processes. By binding to TNF-α, golimumab reduces levels of several inflammatory markers, including C-reactive protein (CRP), interleukin-6 (IL-6), intercellular adhesion molecule 1 (ICAM-1), matrix metalloproteinase-3 (MMP-3), and vascular endothelial growth factor (VEGF). SIMPONI® has been approved in multiple jurisdictions for the treatment of conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
[View Source]